PriceTargets.com logo

GRAIL - GRAL Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $67.00
  • Forecasted Upside: 12.70%
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$59.45 As of 06/17/2026 05:00 PM ET
▲ +1.16 (1.99%)

This chart shows the closing price for GRAL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New GRAIL Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRAL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRAL

Analyst Price Target is $67.00
▲ +12.70% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for GRAIL in the last 3 months. The average price target is $67.00, with a high forecast of $80.00 and a low forecast of $56.00. The average price target represents a 12.70% upside from the last price of $59.45.

This chart shows the closing price for GRAL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 10 investment analysts is to hold stock in GRAIL. This rating has held steady since March 2026, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
5/18/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
6/17/2026

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/5/2026The Goldman Sachs GroupInitiated CoverageNeutral$60.00
6/5/2026The Goldman Sachs GroupInitiated CoverageNeutral$60.00
6/2/2026Wolfe ResearchInitiated CoveragePeer Perform
5/6/2026TD CowenBoost TargetBuy ➝ Buy$65.00 ➝ $69.00
5/6/2026Piper SandlerBoost TargetNeutral ➝ Neutral$54.00 ➝ $56.00
5/6/2026Robert W. BairdSet Target$70.00
4/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
4/10/2026Piper SandlerInitiated CoverageNeutral$54.00
4/10/2026MizuhoInitiated CoverageNeutral$58.00
3/30/2026GuggenheimLower TargetBuy ➝ Buy$130.00 ➝ $75.00
3/18/2026TD CowenUpgradeHold ➝ Buy$65.00
2/24/2026Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$110.00 ➝ $60.00
2/20/2026Robert W. BairdSet Target$82.00
2/20/2026Canaccord Genuity GroupLower TargetBuy ➝ Buy$105.00 ➝ $80.00
2/19/2026TD CowenInitiated CoverageHold ➝ Hold$114.00
2/17/2026Robert W. BairdInitiated CoverageOutperform ➝ Outperform$113.00
2/17/2026Robert W. BairdInitiated CoverageOutperform ➝ Outperform$113.00
1/26/2026GuggenheimBoost TargetBuy ➝ Buy$100.00 ➝ $130.00
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/1/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$85.00 ➝ $110.00
11/17/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$85.00 ➝ $105.00
11/12/2025GuggenheimUpgradeNeutral ➝ Buy$100.00
10/22/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$75.00 ➝ $85.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/3/2025UBS GroupSet Target$75.00
10/3/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$43.00 ➝ $75.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
5/14/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$32.00 ➝ $43.00
4/21/2025Canaccord Genuity GroupInitiated CoverageBuy$32.00
3/18/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$16.00 ➝ $20.00
11/27/2024Morgan StanleyInitiated CoverageEqual Weight$16.00
11/15/2024Wolfe ResearchInitiated CoveragePeer Perform
10/17/2024GuggenheimInitiated CoverageNeutral
(Data available from 6/18/2021 forward)

News Sentiment Rating

0.06 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 26 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
11/19/2025
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/18/2026
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 5 very positive mentions
  • 22 positive mentions
  • 6 negative mentions
  • 7 very negative mentions
Mentions as of
3/19/2026
  • 2 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2026
  • 0 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/18/2026
  • 8 very positive mentions
  • 60 positive mentions
  • 0 negative mentions
  • 7 very negative mentions
Mentions as of
6/17/2026

Current Sentiment

  • 8 very positive mentions
  • 60 positive mentions
  • 0 negative mentions
  • 7 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

GRAIL logo
GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.
Read More

Today's Range

Now: $59.45
Low: $57.51
High: $60.69

50 Day Range

MA: $58.55
Low: $45.63
High: $73.92

52 Week Range

Now: $59.45
Low: $29.95
High: $118.84

Volume

676,691 shs

Average Volume

832,908 shs

Market Capitalization

$2.55 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.15

Frequently Asked Questions

What sell-side analysts currently cover shares of GRAIL?

The following Wall Street analysts have issued stock ratings on GRAIL in the last twelve months: Canaccord Genuity Group Inc., Guggenheim, Mizuho, Morgan Stanley, Piper Sandler, Robert W. Baird, TD Cowen, The Goldman Sachs Group, Inc., UBS Group AG, Wall Street Zen, Weiss Ratings, and Wolfe Research.
View the latest analyst ratings for GRAL.

What is the current price target for GRAIL?

0 Wall Street analysts have set twelve-month price targets for GRAIL in the last year. Their average twelve-month price target is $67.00, suggesting a possible upside of 12.7%. Canaccord Genuity Group Inc. has the highest price target set, predicting GRAL will reach $80.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $56.00 for GRAIL in the next year.
View the latest price targets for GRAL.

What is the current consensus analyst rating for GRAIL?

GRAIL currently has 1 sell rating, 5 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GRAL, but not buy more shares or sell existing shares.
View the latest ratings for GRAL.

What other companies compete with GRAIL?

Other companies that are similar to GRAIL include Hims & Hers Health, PACS Group, Caris Life Sciences, Billiontoone and Sotera Health. Learn More about companies similar to GRAIL.

How do I contact GRAIL's investor relations team?

GRAIL's physical mailing address is 1525 O'brien DRIVE, MENLO PARK, CA, 94025. The company's listed phone number is (650) 771-9796 and its investor relations email address is [email protected]. The official website for GRAIL is grail.com. Learn More about contacing GRAIL investor relations.